The 13 most recent market catalysts affecting $PTGX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Protagonist Therapeutics (PTGX) and raised the price target from $153 to $180. This action signals a strengthened…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190
BMO Capital's analyst Etzer Darout maintained an 'Outperform' rating for Protagonist Therapeutics and raised the price target from $178 to $190. This action signals a strengthened …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
HC Wainwright & Co. analyst Douglas Tsao maintained a 'Buy' rating on Protagonist Therapeutics (PTGX) and raised the price target from $167 to $170. This action signals continued a…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027
This headline is a significant positive catalyst for Protagenic Therapeutics (PTGX). The FDA's 'no objection' to the Phase 1 program design for PT00114 in Generalized Anxiety Disor…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 65
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
BMO Capital's decision to raise Protagonist Therapeutics' price target from $112 to $178, while maintaining an Outperform rating, signals a strong conviction in the company's prosp…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Truist Securities analyst Srikripa Devarakonda maintained a 'Buy' rating on Protagonist Therapeutics (PTGX) and raised the price target from $145 to $170. This action signals a str…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173
Wedbush analyst Yun Zhong has maintained an 'Outperform' rating for Protagonist Therapeutics (PTGX) and raised the price target from $118 to $173. This significant increase in the …
Aug 10, 2026
Market Technicals
Neutral
Impact 65
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
The filing reports multiple analyst upgrades across five different companies: Protagonist Therapeutics, Lincoln Electric Holdings, James Hardie Industries, NetApp Inc, and DICK'S S…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Protagonist Therapeutics shares are trading higher after Barclays raised its price target on the stock from $151 to $153.
The raised price target from Barclays on Protagonist Therapeutics (PTGX) is a positive corporate catalyst, indicating increased analyst confidence in the company's future prospects…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Protagonist Therapeutics (PTGX) and raised the price target from $151 to $153. This action signals continued …
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Protagonist Therapeutics (PTGX) announced Q2 earnings per share of $2.29, significantly surpassing the analyst consensus of $1.66. This represents a massive 516.36% increase from a…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Protagonist Therapeutics (PTGX) and significantly raised the price target from $119 to $151. This action indi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.